✦ LIBER ✦

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

✍ Scribed by Nelson, D.R.; Feld, J.; Kowdley, K.V.; Al-Assi, M.T.; Lin, M.; Mo, H.; McNally, J.; Brainard, D.M.; Symonds, W.T.; McHutchison, J.G.; Patel, K.; Gordon, S.C.

Book ID: 122432762
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 74 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60008-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF

5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)

✍ Gane, E.; Lawitz, E.; Rodriguez-Torres, M.; Gordon, S.; Dvory-Sobol, H.; Arterbu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

O109 ALL ORAL FIXED-DOSE COMBINATION SOF

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

✍ Afdhal, N.; Reddy, R.K.; Pockros, P.; Di Bisceglie, A.M.; Arora, S.; Yang, J.C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 151 KB

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

✍ Jacobson, I.; Yoshida, E.M.; Sulkowski, M.; Nelson, D.R.; Svarovskaia, E.; An, D 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

O164 ALL ORAL FIXED-DOSE COMBINATION SOF

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

✍ Mangia, A.; Marcellin, P.; Kwo, P.; Foster, G.R.; Buti, M.; Bräu, N.; Muir, A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Tu2038 All Oral Fixed-dose Combination S

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

✍ Jacobson, Ira M.; Marcellin, Patrick; Mangia, Alessandra; Kwo, Paul Y.; Foster, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

236 All Oral Fixed-Dose Combination Sofo

236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study

✍ Kwo, Paul Y.; Reddy, K. Rajender; Pockros, Paul J.; Di Bisceglie, Adrian M.; Aro 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 361 KB